Table 2.
Weighted analysis of survival by conditioning regimen of patients in CR1 and CR2.
| Outcome | Strata | n | Day 100 (95% CI) | 1 year (95% CI) | 3 years (95% CI) | 5 years (95% CI) | HR | 95% CI | P value* |
|---|---|---|---|---|---|---|---|---|---|
| CR1 (n = 1483) | |||||||||
| OS | FTBI | 1271 | – | 81.8 (79.7–83.8) | 72.5 (70.1–75.0) | 68.8 (66.3–71.5) | 1.00 | – | 0.25 |
| CC | 212 | – | 83.2 (80.7–85.8) | 77.1 (74.2–80.0) | 74.1 (71.1–77.3) | 0.79 | 0.53–1.17 | ||
| LFS | FTBI | 1271 | – | 74.7 (72.4–77.0) | 65.8 (63.3–68.5) | 63.8 (61.2–66.5) | 1.00 | – | 0.83 |
| CC | 212 | – | 75.4 (72.5–78.4) | 65.5 (62.3–68.9) | 61.4 (58.0–64.9) | 1.03 | 0.76–1.41 | ||
| RI | FTBI | 1271 | – | 13.9 (12.1–16.1) | 20.9 (18.7–23.4) | 22.4 (20.1–25.0) | 1.00 | – | 0.33 |
| CC | 212 | – | 16.9 (11.3–25.3) | 24.9 (17.9–34.5) | 26.9 (19.7–36.9) | 1.20 | 0.83–1.71 | ||
| NRM | FTBI | 1271 | – | 11.4 (9.7–13.3) | 13.3 (11.5–15.4) | 13.8 (11.9–15.9) | 1.00 | – | 0.47 |
| CC | 212 | – | 7.7 (4.1–14.7) | 9.6 (5.5–17.0) | 11.7 (6.9–19.8) | 0.79 | 0.41–1.50 | ||
| aGvHD III–IV | FTBI | 1225 | 11.8 (10.1–13.7) | – | – | – | 1.00 | – | 0.16 |
| CC | 207 | 16.9 (10.7–26.7) | – | – | – | 1.46 | 0.86–2.50 | ||
| cGvHD | FTBI | 1123 | – | 20.0 (17.6–22.6) | 23.3 (20.9–26.1) | 24.3 (21.8–27.1) | 1.00 | – | 0.60 |
| CC | 189 | – | 18.5 (11.8–29.1) | 20.8 (13.7–31.4) | 20.8 (13.7–31.4) | 0.86 | 0.50–1.48 | ||
| cGvHD ext. | FTBI | 1107 | – | 8.2 (6.7–10.0) | 10.4 (8.7–12.4) | 11.3 (9.5–13.4) | 1.00 | – | 0.54 |
| CC | 189 | – | 6.5 (3.1–13.8) | 8.2 (4.3–15.9) | 8.2 (4.3–15.9) | 0.82 | 0.42–1.58 | ||
| CR2 (n = 1549) | |||||||||
| OS | FTBI | 1339 | – | 73.1 (70.8–75.4) | 61.9 (59.4–64.5) | 58.8 (56.2–61.6) | 1.00 | – | <0.0001 |
| CC | 210 | – | 61.0 (58.1–64.1) | 44.1 (41.1–47.4) | 35.9 (33.0–39.1) | 1.75 | 1.36–2.27 | ||
| LFS | FTBI | 1339 | – | 65.1 (62.6–67.6) | 55.5 (52.9–58.2) | 53.7 (51.1–56.5) | 1.00 | – | <0.0001 |
| CC | 210 | – | 45.9 (43.0–49.1) | 34.2 (31.3–37.3) | 29.4 (26.6–32.5) | 1.80 | 1.43–2.25 | ||
| RI | FTBI | 1339 | – | 21.9 (19.7–24.3) | 29.5 (27.0–32.2) | 30.6 (28.1–33.3) | 1.00 | – | <0.0001 |
| CC | 210 | – | 35.4 (27.3–45.9) | 45.6 (36.8–56.5) | 49.3 (40.3–60.2) | 1.96 | 1.44–2.67 | ||
| NRM | FTBI | 1339 | – | 13.0 (11.3–15.0) | 15.0 (13.2–17.2) | 15.7 (13.8–17.9) | 1.00 | – | 0.044 |
| CC | 210 | – | 18.7 (12.7–27.4) | 20.2 (14.1–29.0) | 21.3 (15.1–30.2) | 1.51 | 1.01–2.25 | ||
| aGvHD III–IV | FTBI | 1274 | 13.1 (11.4–15.1) | – | – | – | 1.00 | – | 0.36 |
| CC | 204 | 10.6 (6.5–17.2) | – | – | – | 0.80 | 0.51–1.28 | ||
| cGvHD | FTBI | 1192 | – | 17.9 (15.7–20.4) | 20.5 (18.1–23.1) | 21.2 (18.8–23.9) | 1.00 | – | 0.064 |
| CC | 184 | – | 25.3 (17.7–36.2) | 25.8 (18.1–36.7) | 26.0 (18.3–36.9) | 1.52 | 0.98–2.37 | ||
| cGvHD ext. | FTBI | 1178 | – | 7.5 (6.1–9.3) | 9.6 (8.0–11.5) | 9.9 (8.3–11.9) | 1.00 | – | 0.075 |
| CC | 184 | – | 9.5 (5.7–16.1) | 10.0 (6.0–16.5) | 10.1 (6.2–16.7) | 1.64 | 0.95–2.84 | ||
a/cGvD acute/chronic graft versus host disease, CC chemotherapy-based conditioning, CI confidence interval, CR1 first complete remission, CR2 second complete remission, ext. extensive, FTBI fractionated total body irradiation, HR Hazard ratio, LFS leukemia-free survival, NRM nonrelapse mortality, OS overall survival, RI relapse incidence.
*Wald test in a weighted Cox model taking into account the center effect (cause specific for RI, NRM, and GvHD outcomes).